Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Transdermal immunotherapy: Past, present and future.
Cell death of spinal cord ED1(+) cells in a rat model of multiple sclerosis.
Development of Ms Budget Manager: A Practical Tool to Assist Alternative Stakeholders At Multiple Decision Levels In The Forecast And Financial Management For Multiple Sclerosis (Ms).
Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis.
Patterns Of Use Of Tests To Monitor Disease Activity Among Patients Currently Treated For Relapsing Remitting Multiple Sclerosis (Rrms) In Europe.
Disease Activity during the First Year Predicts Clinical Long-Term Outcomes in Patients with Multiple Sclerosis: Fingolimod Treatment Benefit
Cost-Effectiveness of New Therapies for Multiple Sclerosis In Spain.
[Target Molecule for a Demyelinating Type of Guillain-Barré Syndrome, Acute Inflammatory Demyelinating Polyneuropathy].
A white matter lesion-filling approach to improve brain tissue volume measurements.
Influence of Formal Education on Cognitive Reserve in Patients with Multiple Sclerosis.
Protein misfolding and clearance in demyelinating peripheral neuropathies: Therapeutic implications.
Fingolimod and cardiac risk: latest findings and clinical implications.
Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders.
Clinical perspectives of TRAIL: insights into central nervous system disorders.
Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease.
Regulation of oligodendrocyte precursor maintenance by chondroitin sulphate glycosaminoglycans.
Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation.
Rituximab in Turkish neuromyelitis optica patients with limited response to other immunosuppressants.
Lotensin: Cheap 180
Studying the Effects of Semaphorins on Oligodendrocyte Lineage Cells.
Cellulose/soy protein composite-based nerve guidance conduits with designed microstructure for peripheral nerve regeneration.
Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.
Positive association of vitamin d receptor gene variations with multiple sclerosis in South East Iranian population.
Budget Impact Analysis of Delayed-Release Dimethylfumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy.
[Protocol for neurophysiological studies of the pelvic floor to appraise anorectal dysfunction in patients with multiple sclerosis].
Pages
« first
‹ previous
…
717
718
719
720
721
722
723
724
725
…
next ›
last »